Jeff Thomas

Mr. Jeff Thomas


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2017 in Human Genetics
Verified
Journal Article
Closed access
PDF file
MWMaureen Wilson-Genderson
Maureen Wilson-Genderson
KBK. Laura Barker
K. Laura Barker
HGHeather M. Gardiner
Heather M. Gardiner
MMMaghboeba Mosavel
Maghboeba Mosavel
JTJeff Thomas
Jeff Thomas
LSLaura A. Siminoff
Laura A. Siminoff

12 January 2026 in Targets
Verified
Journal Article
Open access
PDF file
EOEmily O'Brien
Emily O'Brien
DDDhruva Mitul Dave
Dhruva Mitul Dave
AKAbbie Kleckley
Abbie Kleckley
FOFibiana Oladipo
Fibiana Oladipo
CMChristopher M. Mayer
Christopher M. Mayer
RARebecca Arend
Rebecca Arend
Background/Objectives: This pilot study investigates the feasibility of using patient-derived microtumors (PDMs) to assess chemotherapy response in epithelial ovarian cancer. Methods: Fresh tissue from 10 patients was used to develop PDMs, which were then tested against carboplatin/paclitaxel, carboplatin/docetaxel, and carboplatin/pegylated liposomal doxorubicin (PLD). Of the 10 PDMs, 3 were obtained from primary debulking surgery (PDS), and 7 were obtained at the time of interval debulking surgery following neoadjuvant chemotherapy. Results: When looking at PDMs derived from tissue collected at the time of PDS, we found that 100% of PDMs demonstrated a full response to carboplatin/PLD, while 30% showed a full response to all regimens, all of which were derived from high-grade serous carcinoma during PDS. The remaining PDMs showed moderate responses to carbo/taxol and carbo/doce. Conclusions: This study suggests that PDMs can be used to assess the efficacy of chemotherapy regimens, as a hypothesis-generating step toward future predictive validation.